본문 바로가기
KERD
논문KCI 등재

Monoclonal Antibody Therapies for Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder

김호진|김우준
대한신경과학회 (Korean Neurological Association)|2020.07|Journal of Clinical Neurology|제16권 제3호|pp. 355-368

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

treatmentefficacysafety.monoclonal antibodymultiple sclerosisneuromyelitis optica spectrum disorder

초록

Considerable progress has been made in treatments for multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) over the last several decades. However, the present treatments do not show satisfactory efficacy or safety in a considerable proportion of patients, who experience relapse or disability progression despite receiving treatment and suffer from side effects, which can be severe. Improvements in the understanding of the pathophysiologies of MS and NMOSD have led to numerous therapeutic approaches being proposed and developed. Monoclonal antibodies (mAbs) are receiving increasing attention because of their specificity of action and likelihood of high efficacy with fewer side effects. Many mAbs have been evaluated, and some have been approved for MS or NMOSD treatment. This article reviews the use of mAbs for treating MS and NMOSD, including summarizing their mechanisms of action, efficacy, and safety profiles.

Abstract

Considerable progress has been made in treatments for multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) over the last several decades. However, the present treatments do not show satisfactory efficacy or safety in a considerable proportion of patients, who experience relapse or disability progression despite receiving treatment and suffer from side effects, which can be severe. Improvements in the understanding of the pathophysiologies of MS and NMOSD have led to numerous therapeutic approaches being proposed and developed. Monoclonal antibodies (mAbs) are receiving increasing attention because of their specificity of action and likelihood of high efficacy with fewer side effects. Many mAbs have been evaluated, and some have been approved for MS or NMOSD treatment. This article reviews the use of mAbs for treating MS and NMOSD, including summarizing their mechanisms of action, efficacy, and safety profiles.

참고문헌 (117)

  1. Jeong IH, "Comparative analysis of treatment outcomes in patients with neuromyelitis optica spectrum disorder using multifaceted endpoints", Mult Scler, 22, pp.329~339 (2016)
  2. Kim SH, "Treatment outcomes with rituximab in 100 patients with neuromyelitis optica: influence of FCGR3A polymorphisms on the therapeutic response to rituximab", JAMA Neurol, 72, pp.989~995 (2015)
  3. Wootla B, "Recent advances in monoclonal antibody therapies for multiple sclerosis", Expert Opin Biol Ther, 16, pp.827~839 (2016)
  4. Voge NV, "Monoclonal antibodies in multiple sclerosis : present and future", Biomedicines, 7, pp.20~ (2019)
  5. Ciron J, "Recommendations for the use of Rituximab in neuromyelitis optica spectrum disorders", Rev Neurol (Paris), 174, pp.255~264 (2018)
  6. Yednock TA, "Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin", Nature, 356, pp.63~66 (1992)
  7. Polman CH, "A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis", N Engl J Med, 354, pp.899~910 (2006)
  8. Rudick RA, "Natalizumab plus interferon beta-1a for relapsing multiple sclerosis", N Engl J Med, 354, pp.911~923 (2006)
  9. Langer-Gould A, "Progressive multifocal leukoencephalopathy in a patient treated with natalizumab", N Engl J Med, 353, pp.375~381 (2005)
  10. Kleinschmidt-DeMasters BK, "Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis", N Engl J Med, 353, pp.369~374 (2005)
  11. Van Assche G, "Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease", N Engl J Med, 353, pp.362~368 (2005)
  12. Clerico M, "Natalizumab in multiple sclerosis : long-term management", Int J Mol Sci, 18, pp.940~ (2017)
  13. Kapoor R, "Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, doubleblind, placebo-controlled trial with an open-label extension", Lancet Neurol, 17, pp.405~415 (2018)
  14. Clerico M, "Long-term safety evaluation of natalizumab for the treatment of multiple sclerosis", Expert Opin Drug Saf, 16, pp.963~972 (2017)
  15. O’Connor P, "Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study", Neurology, 83, pp.78~86 (2014)
  16. Goodman AD, "GLANCE : results of a phase 2, randomized, double-blind, placebo-controlled study", Neurology, 72, pp.806~812 (2009)
  17. Butzkueven H, "Efficacy and safety of natalizumab in multiple sclerosis : interim observational programme results", J Neurol Neurosurg Psychiatry, 85, pp.1190~1197 (2014)
  18. Ho PR, "Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies", Lancet Neurol, 16, pp.925~933 (2017)
  19. Plavina T, "Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy", Ann Neurol, 76, pp.802~812 (2014)
  20. Major EO, "Pathogenesis of progressive multifocal leukoencephalopathy and risks associated with treatments for multiple sclerosis: a decade of lessons learned", Lancet Neurol, 17, pp.467~480 (2018)
  21. Berger JR, "Considerations on discontinuing natalizumab for the treatment of multiple sclerosis", Ann Neurol, 68, pp.409~411 (2010)
  22. O’Connor PW, "Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis", Neurology, 76, pp.1858~1865 (2011)
  23. Sangalli F, "Long-term management of natalizumab discontinuation in a large monocentric cohort of multiple sclerosis patients", Mult Scler Relat Disord, 3, pp.520~526 (2014)
  24. Sellner J, "A review of the evidence for a natalizumab exit strategy for patients with multiple sclerosis", Autoimmun Rev, 18, pp.255~261 (2019)
  25. Alping P, "Rituximab versus fingolimod after natalizumab in multiple sclerosis patients", Ann Neurol, 79, pp.950~958 (2016)
  26. Malucchi S, "High-risk PML patients switching from natalizumab to alemtuzumab : an observational study", Neurol Ther, 6, pp.145~152 (2017)
  27. Federle L, "Alemtuzumab as rescue therapy in case of multiple sclerosis rebound following natalizumab break : clinical case and literature review", Mult Scler Relat Disord, 30, pp.262~264 (2019)
  28. Ambrose LR, "Neutrophils express CD52 and exhibit complement-mediated lysis in the presence of alemtuzumab", Blood, 114, pp.3052~3055 (2009)
  29. Hale G, "From laboratory to clinic : the story of CAM PA TH-1", Methods Mol Med, 40, pp.243~266 (2000)
  30. Garnock-Jones KP, "Alemtuzumab : a review of its use in patients with relapsing multiple sclerosis", Drugs, 74, pp.489~504 (2014)
  31. CAMMS223 Trial Investigators, "Alemtuzumab vs. interferon beta-1a in early multiple sclerosis", N Engl J Med, 359, pp.1786~1801 (2008)
  32. Cohen JA, "Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial", Lancet, 380, pp.1819~1828 (2012)
  33. Coles AJ, "Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3trial", Lancet, 380, pp.1829~1839 (2012)
  34. Azzopardi L, "Alemtuzumab use in neuromyelitis optica spectrum disorders: a brief case series", J Neurol, 263, pp.25~29 (2016)
  35. Havrdova E, "Alemtuzumab in the treatment of multiple sclerosis : key clinical trial results and considerations for use", Ther Adv Neurol Disorder, 8, pp.31~45 (2015)
  36. Evan JR, "Alemtuzumab for the treatment of multiple sclerosis", Expert Opin Biol Ther, 18, pp.323~334 (2018)
  37. Waggoner J, "Progressive multifocal leukoencephalopathy following heightened immunosuppression after lung transplant", J Heart Lung Transplant, 28, pp.395~398 (2009)
  38. Isidoro L, "Progressive multifocal leukoencephalopathy in a patient with chronic lymphocytic leukaemia treated with alemtuzumab", BMJ Case Rep (2014)
  39. McCall B, "Alemtuzumab to be restricted pending review, says EMA", Lancet, 393, pp.1683~ (2019)
  40. Cohan SL, "Daclizumab: mechanisms of action, therapeutic efficacy, adverse events and its uncovering the potential role of innate immune system recruitment as a treatment strategy for relapsing multiple sclerosis", Biomedicines, 7, pp.E18~ (2019)
  41. Baldassari LE, "Daclizumab : development, clinical trials, and practical aspects of use in multiple sclerosis", Neurotherapeutics, 14, pp.842~858 (2017)
  42. Bianchi A, "Daclizumab-induced encephalitis in multiple sclerosis", Mult Scler, 25, pp.1557~1559 (2019)
  43. Waldmann TA, "Therapy of patients with human T-cell lymphotrophic virus I-induced adult T-cell leukemia with anti-Tac, a monoclonal antibody to the receptor for interleukin-2", Blood, 72, pp.1805~1816 (1988)
  44. Vincenti F, "Interleukin2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation", N Engl J Med, 338, pp.161~165 (1998)
  45. Nussenblatt RB, "Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb : a phase I", II clinical trial, 1999, pp.96, 7462~7466
  46. Bumgardner GL, "Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplan-tation", Transplantation, 72, pp.839~845 (2001)
  47. Wynn D, "Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta", Lancet Neurol, 9, pp.381~390 (2010)
  48. Gold R, "Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebocontrolled trial", Lancet, 381, pp.2167~2175 (2013)
  49. Giovannoni G, "Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, doubleblind extension trial", Lancet Neurol, 13, pp.472~481 (2014)
  50. Gold R, "Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study", BMC Neurol, 16, pp.117~ (2016)
  51. Kappos L, "Daclizumab HYP versus interferon beta-1a in relapsing multiple sclerosis", N Engl J Med, 373, pp.1418~1428 (2015)
  52. Giovannoni G, "Safety and tolerability profile of daclizumab in patients with relapsing-remitting multiple sclerosis : an integrated analysis of clinical studies", Mult Scler Relat Disord, 9, pp.36~46 (2016)
  53. Stork L, "Severe meningo-", encephalitis after daclizumab therapy for multiple sclerosis, 2019, pp.25, 1618~1632
  54. 김우준, "New Insights into Neuromyelitis Optica", Journal of Clinical Neurology, 7(3), pp.115~127 (2011), 대한신경과학회
  55. Damato V, "Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders : a systematic review and meta-analysis", JAMA Neurol, 73, pp.1342~1348 (2016)
  56. Sato D, "Treatment of neuromyelitis optica: an evidence based review", Arq Neuropsiquiatr, 70, pp.59~66 (2012)
  57. Hauser SL, "B-cell depletion with rituximab in relapsing-remitting multiple sclerosis", N Engl J Med, 358, pp.676~688 (2008)
  58. Salzer J, "Rituximab in multiple sclerosis : a retrospective observational study on safety and efficacy", Neurology, 87, pp.2074~2081 (2016)
  59. Naismith RT, "Rituximab add-on therapy for breakthrough relapsing multiple sclerosis : a 52-week phase II trial", Neurology, 74, pp.1860~1867 (2010)
  60. Hu Y, "Efficacy and safety of rituximab for relapsing-remitting multiple sclerosis : a systematic review and meta-analysis", Autoimmun Rev, 18, pp.542~548 (2019)
  61. Hawker K, "Rituximab in patients with primary progressive multiple sclerosis : results of a randomized double-blind placebo-controlled multicenter trial", Ann Neurol, 66, pp.460~471 (2009)
  62. Cree BAC, "An open label study of the effects of rituximab in neuromyelitis optica", Neurology, 64, pp.1270~1272 (2005)
  63. Jarius S, "Antibody to aquaporin-4 in the long-term course of neuromyelitis optica", Brain, 131, pp.3072~3080 (2008)
  64. Jacob A, "Treatment of neuromyelitis optica with rituximab : retrospective analysis of 25 patients", Arch Neurol, 65, pp.1443~1448 (2008)
  65. Kim SH, "Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years", Arch Neurol, 68, pp.1412~1420 (2011)
  66. Gao F, "Effectiveness of rituximab in neuromyelitis optica : a meta-analysis", BMC Neurol, 19, pp.36~ (2019)
  67. Evens AM, "Rituximab-associated hepatitis B virus(HBV)reactivation in lymphoproliferative diseases : meta-analysis and examination of FDA safety reports", Ann Oncol, 22, pp.1170~1180 (2011)
  68. Smalls DJ, "Hepatitis B virus reactivation : risk factors and current management strategies", Pharmacotherapy, 39, pp.1190~1203 (2019)
  69. European Association for the Study of the Liver, "EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection", J Hepatol, 67, pp.370~398 (2017)
  70. Molloy ES, "Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: are patients with systemic lupus erythematosus at particular risk?", Autoimmun Rev, 8, pp.144~146 (2008)
  71. Clifford DB, "Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis", Arch Neurol, 68, pp.1156~1164 (2011)
  72. Kalisch A, "Progressive multifocal leukoencephalopathy in patients with a hematological malignancy : review of therapeutic options", Chemotherapy, 60, pp.47~53 (2014)
  73. Marcinnò A, "Rituximab-induced hypogammaglobulinemia in patients with neuromyelitis optica spectrum disorders", Neurol Neuroimmunol Neuroinflamm, 5, pp.e498~ (2018)
  74. Akaishi T, "Efficiency of antibody therapy in demyelinating diseases", Int Immunol, 29, pp.327~335 (2017)
  75. "FDA approves new drug to treat multiple sclerosis" (2018)[URL]
  76. Kappos L, "Ocrelizumab in relapsing-remitting multiple sclerosis : a phase 2, randomised, placebo-controlled, multicentre trial", Lancet, 378, pp.1779~1787 (2011)
  77. Hauser SL, "Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis", N Engl J Med, 376, pp.221~234 (2017)
  78. Barkhof F, "Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis", Neurology, 93, pp.e1778~e1786 (2019)
  79. Montalban X, "Ocrelizumab versus placebo in primary progressive multiple sclerosis", N Engl J Med, 376, pp.209~220 (2017)
  80. Teeling JL, "The biological activity of human CD20monoclonal antibodies is linked to unique epitopes on CD20", J Immunol, 177, pp.362~371 (2006)
  81. Bleeker WK, "Estimation of dose requirements for sustained in vivo activity of a therapeutic human anti-CD20 antibody", Br J Haematol, 140, pp.303~312 (2008)
  82. Bar-Or A, "Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis : the MIRROR study", Neurology, 90, pp.e1805~e1814 (2018)
  83. Sorensen PS, "Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis : a phase 2 study", Neurology, 82, pp.573~581 (2014)
  84. D’Arena G, "Quantitative flow cytometry for the differential diagnosis of leukemic B-cell chronic lymphoproliferative disorders", Am J Hematol, 64, pp.275~281 (2000)
  85. Cooper LJN, "Development and application of CD19-specific T cells for adoptive immunotherapy of B cell malignancies", Blood Cells Mol Dis, 33, pp.83~89 (2004)
  86. Agius MA, "Safety and tolerability of inebilizumab (MEDI551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study", Mult Scler, 25, pp.235~245 (2019)
  87. Cree BAC, "Wingerchuk DM, et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2", 3 trial, 2019, pp.394, 1352~1363
  88. Le Garff-Tavernier M, "Antibody-dependent cellular cytotoxicity of the optimized anti-CD20 monoclonal antibody ublituximab on chronic lymphocytic leukemia cells with the 17p deletion", Leukemia, 28, pp.230~233 (2014)
  89. Final Results of a Placebo Controlled, Phase 2 Multicenter Study of Ublituximab (UTX), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Patients with Relapsing Forms of Multiple Sclerosis (RMS), "Fox E", European Committee for Treatment and Research in Multiple Sclerosis, ~ (2019)
  90. Mealy MA, "A pilot safety study of ublituximab, a monoclonal antibody against CD20, in acute relapses of neuromyelitis optica spectrum disorder", Medicine(Baltimore), 98, pp.e15944~ (2019)
  91. Thomas TC, "Inhibition of complement activity by humanized antiC5 antibody and single-chain Fv", Mol Immunol, 33, pp.1389~1401 (1996)
  92. Pittock SJ, "Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder", N Engl J Med, 381, pp.614~625 (2019)
  93. Pittock SJ, "Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders : an open-label pilot study", Lancet Neurol, 12, pp.554~562 (2013)
  94. Dmytrijuk A, "FDA report : eculizumab(Soliris)for the treatment of patients with paroxysmal nocturnal hemoglobinuria", Oncologist, 13, pp.993~1000 (2008)
  95. Nishimoto N, "Inhibition of IL-6 for the treatment of inflammatory diseases", Curr Opin Pharmacol, 4, pp.386~391 (2004)
  96. Arango Duque G, "Macrophage cytokines : involvement in immunity and infectious diseases", Front Immunol, 5, pp.491~ (2014)
  97. Collongues N, "Pharmacotherapy for neuromyelitis optica spectrum disorders : current management and future options", Drugs, 79, pp.125~142 (2019)
  98. Uzawa A, "Interleukin-6 analysis of 572 consecutive CSF samples from neurological disorders : a special focus on neuromyelitis optica", Clin Chim Acta, 469, pp.144~149 (2017)
  99. Burmester GR, "Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA)", Ann Rheum Dis, 75, pp.68~74 (2016)
  100. Ayzenberg I, "Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy", JAMA Neurol, 70, pp.394~397 (2013)
  101. Kieseier BC, "Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica : implication for cellular immune responses", JAMA Neurol, 70, pp.390~393 (2013)
  102. Araki M, "Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica : a pilot study", Neurology, 82, pp.1302~1306 (2014)
  103. Lauenstein AS, "Treating neuromyelitis optica with the interleukin-6 receptor antagonist tocilizumab", BMJ Case Rep, 2014 (2014)
  104. Harmel J, "Interferon-β-related tumefactive brain lesion in a Caucasian patient with neuromyelitis optica and clinical stabilization with tocilizumab", BMC Neurol, 14, pp.247~ (2014)
  105. Ringelstein M, "Long-term therapy with interleukin 6 receptor blockade in highly active neuromyelitis optica spectrum disorder", JAMA Neurol, 72, pp.756~763 (2015)
  106. Gout T, "Lower gastrointestinal perforation in rheumatoid arthritis patients treated with conventional DMARDs or tocilizumab : a systematic literature review", Clin Rheumatol, 30, pp.1471~1474 (2011)
  107. Iwasa T, "Multiple ulcers in the small and large intestines occurred during tocilizumab therapy for rheumatoid arthritis", Endoscopy, 43, pp.70~72 (2011)
  108. Beauchemin P, "MS arising during tocilizumab therapy for rheumatoid arthritis", Mult Scler, 22, pp.254~256 (2016)
  109. Igawa T, "Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization", Nat Biotechnol, 28, pp.1203~1207 (2010)
  110. de Seze J, "A Double-blind Placebo-controlled Study of Satralizumab (SA237), a Recycling Anti-IL-6 Receptor Monoclonal Antibody, as Add-on Therapy for Neuromyelitis Optica Spectrum Disorder (NMOSD)", Proceedings of European Committee for Treatment and Research in Multiple Sclerosis (2018)
  111. Traboulsee A, "Efficacy and Safety of Satralizumab Monotherapy for Relapse Prevention in Neuromyelitis Optica Spectrum Disorder (NMOSD):Results from SAkuraStar, a Double-blind, Placebo-controlled, Phase 3Clinical Study", Proceedings of European Committee for Treatment and Research in Multiple Sclerosis (2019)
  112. Mi S, "LINGO-1 negatively regulates myelination by oligodendrocytes", Nat Neurosci, 8, pp.745~751 (2005)
  113. Mi S, "LINGO-1 is a component of the Nogo-66 receptor", p75 signaling complex, 2004, pp.7, 221~228
  114. Cadavid D, "Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial", Lancet Neurol, 16, pp.189~199 (2017)
  115. Cadavid D, "Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebocontrolled, phase 2 trial", Lancet Neurol, 18, pp.845~856 (2019)
  116. "Efficacy and safety of BIIB033 (opicinumab) as an add-on therapy to disease-modifying therapies (DMTs) in relapsing multiple sclerosis (MS) (AFFINITY)" (2019)[URL]
  117. 김우준, "Oral Disease-Modifying Therapies for Multiple Sclerosis", Journal of Clinical Neurology, 11(1), pp.9~19 (2015), 대한신경과학회[DOI]

관련 논문AI추천

시신경척수염범위질환 치료의 최신 지견김수현대한신경과학회 · 대한신경과학회지2022 · 제40권 제1호Current Updates on the Diagnosis and Management of Multiple Sclerosis for the General NeurologistArchit B Baskaran, Edith L Graham, Elena Grebenciucova, Thomas Shoemaker대한신경과학회 · Journal of Clinical Neurology2023 · 제19권 제3호Early relapse after rituximab treatment in a patient with seronegative neuromyelitis optica spectrum disorder: a case reportJu-Hee Lee, Yoon-Ho Hong대한임상신경생리학회 · Annals of Clinical Neurophysiology2024 · 제26권 제2호다발경화증과 시신경척수염범주질환의 감별진단김남희대한신경과학회 · 대한신경과학회지2016 · 제34권 제4호New Insights into Neuromyelitis Optica김수현, 김우준, 김호진대한신경과학회 · Journal of Clinical Neurology2011 · 제7권 제3호Clinical Efficacy of Plasmapheresis in Patients with Neuromyelitis Optica Spectrum Disorder and Effects on Circulating Anti-Aquaporin-4 Antibody Levels김수현, 김우준, 김호진, 이규임, 정인자, 허소영대한신경과학회 · Journal of Clinical Neurology2013 · 제9권 제1호

이 간행물의 다른 논문 (25건)

Tuberculous Myelopathy Associated with Longitudinally Extensive Lesion: A Clinicoradiological Review of Reported CasesMohamad Syafeeq Faeez Md Noh, Norafida Bahari, Anna Misyail Abdul Rashidpp. 369-375Acute Flaccid Myelitis: Current Status and Diagnostic ChallengesRuksana Huda, Xiang Fangpp. 376-382Refining General Principles of Antiepileptic Drug Treatments for Epilepsy김근태, 노영주, 김동욱, 김대영, 강경욱, 서종근, 조용원, 이순태, 양광익, 변정익pp. 383-389Alterations in Structural and Functional Connectivities in Patients with End-Stage Renal Disease박봉수, 서솔아, 박진한, 이유진, 김일환, 이호준, 김시은, 김양욱, 박시형, 박강민pp. 390-400Effects of Evening Exposure to Light from Organic Light-Emitting Diodes on Melatonin and Sleep조재욱, 조현진, 최수정, 박혜리, 주은연pp. 401-407
원문 보기